Key Data and Practice Considerations for Agents Targeting HER2

Panelists discuss how trastuzumab deruxtecan demonstrated a 22% overall response rate in patients with biliary tract cancer (56.3% in HER2 3+ patients) with 7.4 months progression-free survival in the tumor-agnostic DESTINY-PanTumor02 trial, while zanidatamab showed a 52% confirmed response rate with 7.2 months progression-free survival in HER2 3+ patients in the biliary-specific HERIZON-BTC-01 trial, with treatment selection between these agents requiring individualized case-by-case decisions based on toxicity profiles, dosing schedules, and patient-specific factors since no head-to-head comparison data exist.

administrator

Related Articles